Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.
Tirzepatide is a dual GIP and GLP-1 receptor agonist with a 5-day half-life, demonstrating greater weight loss than semaglutide in head-to-head trials. Sold as Mounjaro (T2D) and Zepbound (obesity); widely compounded.
Tirzepatide is a dual GIP and GLP-1 receptor agonist with a 5-day half-life, demonstrating greater weight loss than semaglutide in head-to-head trials. Sold as Mounjaro (T2D) and Zepbound (obesity); widely compounded. Mechanism: GIP / GLP-1 dual agonist. Typical route: Subcutaneous injection. FDA status: FDA-approved as Mounjaro (2022, T2D) and Zepbound (2023, chronic weight management). Compounded tirzepatide is dispensed under the same FDA compounding framework as semaglutide and is subject to the A
Drug classGIP / GLP-1 dual agonist
Half-life~5 days (weekly dosing)
RouteSubcutaneous injection
Typical maintenance10-15 mg/week
FDA statusApproved (Mounjaro, Zepbound)
Compounded availability503A pharmacies, patient-specific; not FDA-approved
Mechanism of action
Tirzepatide simultaneously activates the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. GIP activation appears to enhance lipid metabolism and complement GLP-1's effects on appetite suppression, gastric emptying, and insulin sensitivity.
Dosing reference
Standard titration: 2.5 mg/week (weeks 1-4), 5 mg/week (weeks 5-8), 7.5 mg/week (weeks 9-12), 10 mg/week (weeks 13-16), with optional escalation to 12.5 or 15 mg/week. Maintenance is typically 10-15 mg/week. Compounded versions commonly use 10, 20, or 40 mg/mL.
Dosing information is provided for educational reference and is not medical advice. Patients should not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.
FDA status & regulatory framework
FDA-approved as Mounjaro (2022, T2D) and Zepbound (2023, chronic weight management). Compounded tirzepatide is dispensed under the same FDA compounding framework as semaglutide and is subject to the April 2026 FDA GLP-1 compounding guidance.
$99 on 6 months · $105 on 3 months · $109 month to month. The same price at every dose and no membership fee (nexlife.us plan page, read November 6, 2026).
Included in the price: the medication, medical guidance from NexLife Medical Group, a GLP-1 nutrition plan, a 1:1 call with a certified wellness coach, 24/7 support and free expedited shipping. Lab work is not listed as included.
Pharmacies named on its plan pages:Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA), described as state-licensed 503A compounding pharmacies.
Trade-offs: compounded semaglutide is not FDA-approved and is not Wegovy or Ozempic. Cash pay only (FSA/HSA cards accepted for eligible portions). Cancellations take effect after 30 days, so one more shipment may be charged. A prescription depends on a licensed clinician’s review.
$119 on 6 months · $125 on 3 months · $129 month to month. The same price at every dose and no membership fee (nexlife.us plan page, read November 6, 2026).
Included in the price: the medication, medical guidance from NexLife Medical Group, a GLP-1 nutrition plan, a 1:1 call with a certified wellness coach, 24/7 support and free expedited shipping. Lab work is not listed as included.
Pharmacies named on its plan pages:Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA), described as state-licensed 503A compounding pharmacies.
Trade-offs: compounded tirzepatide is not FDA-approved and is not Zepbound or Mounjaro. Cash pay only (FSA/HSA cards accepted for eligible portions). Cancellations take effect after 30 days, so one more shipment may be charged. A prescription depends on a licensed clinician’s review.
U.S. telehealth providers that work with Tirzepatide
Tirzepatide activates both the GIP and GLP-1 receptors, while semaglutide is a GLP-1-only agonist. In the SURMOUNT-1 trial, tirzepatide produced 20.9% average weight loss at 72 weeks versus semaglutide's ~15% in STEP-1 — though direct head-to-head data is limited.
Is compounded tirzepatide safe?
Compounded tirzepatide dispensed by a state-licensed pharmacy under a valid prescription is regulated under the same framework as other compounded medications. Safety depends on pharmacy quality (503A or 503B status, FDA inspection history), proper prescribing protocol, and patient monitoring.
Who is the Editor's Pick for compounded tirzepatide?
NexLife is our editor’s pick for compounded tirzepatide, scoring 94/100 on our v4.1 methodology. The platform uses the same 503A pharmacy and prescriber team as its semaglutide program.
Jastreboff AM, Aronne LJ, Ahmad NN, et al.Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1).N Engl J Med. 2022;387(3):205-216.PMID: 35658024
Frías JP, Davies MJ, Rosenstock J, et al.Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2).N Engl J Med. 2021;385(6):503-515.PMID: 34170647
Aronne LJ, Sattar N, Horn DB, et al.Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4).JAMA. 2024;331(1):38-48.PMID: 38078870
U.S. Food and Drug Administration.FDA Approves New Medication for Chronic Weight Management.FDA News Release. November 8, 2023.View source
Sources are peer-reviewed where available. PubMed (PMID) links resolve to NCBI's PubMed database. FDA links resolve to the U.S. Food and Drug Administration. Citations were last verified 2026-05-11.